Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.59 |
| ▸ | CA2 | P00918 | 7/20 | 0.59 |
| ▸ | CA9 | Q16790 | 7/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15559114 | 0.91 | CA1 (0.60) | CA1CA2CA9EPHX2PTGS2 | |
| SCHEMBL15552223 | 0.88 | CA1 (0.65) | CA1CA2CA9EPHX2PTGS2 | |
| SCHEMBL15549889 | 0.81 | CA1 (0.71) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL16810167 | 0.80 | CA1 (0.57) | CA1CA2CA9EPHX2PTGS2 | |
| SCHEMBL19759267 | 0.80 | PTGS2 (0.69) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL15550607 | 0.79 | CA1 (0.69) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL19759270 | 0.78 | CA1 (0.54) | CA1CA2CA9EPHX2PTGS2 | |
| SCHEMBL19234874 | 0.78 | CA1 (0.54) | CA1CA2CA9EPHX2PTGS2 | |
| SCHEMBL19759268 | 0.77 | PTGS2 (0.60) | CA1CA2CA9EPHX2PTGS2 | |
| SCHEMBL15552398 | 0.77 | PTGS2 (0.69) | CA1CA2CA9EPHX2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002290-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF STAT3 | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002290-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF STAT3 | STAT3, STAT6, JAK2 | CA1 4137/4885CA2 3692/4885CA9 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.